Rage-targeted antisense oligonucleotides
CL202601110A1Pending Publication Date: 2026-07-17RAGE BIOTECH PTY LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CL202601110
- Authority / Receiving Office
- CL · CL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-18
- Filing Date
- 2026-04-08
- Publication Date
- 2026-07-17
Abstract
The present invention relates to potent antisense oligonucleotides that modify splicing, modulating the alternative splicing of pre-mRNA encoding the Receptor of Advanced Glycation End Products (RAGE) or a portion thereof, and methods for treating RAGE-related disorders using such antisense oligonucleotides. In one aspect, the present invention provides an antisense oligonucleotide (AON) consisting of the nucleotide sequence TGCCGCCTTTGCCACAAG (5-3; SEC ID NO: 1); or GCCGCCTTTGCCACAAGA (5-3; SEC ID NO: 2), preferably wherein the antisense oligonucleotide comprises at least one modified nucleotide.
Need to check novelty before this filing date? Find Prior Art